12:00 AM
Feb 04, 2013
 |  BC Week In Review  |  Clinical News  |  Regulatory

Avastin bevacizumab regulatory update

Roche disclosed in its 4Q12 earnings that the European Commission approved an expansion of the label of Avastin bevacizumab to include second-line therapy with the cancer drug plus chemotherapy in metastatic colorectal cancer (mCRC) patients who progressed after first-line treatment with Avastin. EMA's CHMP issued a positive opinion for the additional indication last November (see BioCentury, Dec. 3, 2012). FDA approved the humanized mAb against VEGF for the indication last month (see BioCentury, Jan. 28). Avastin is also approved in the U.S. and EU for first- and second-line treatment of...

Read the full 428 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >